Compare Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) vs Rivian Automotive, Inc. (RIVN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Maravai LifeSciences Holdings Inc. Class A Common Stock vs Rivian Automotive, Inc. — how do they compare? Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $977.37M), while Rivian Automotive, Inc. trades at $12.84 (market cap $18.75B). The key difference: Rivian Automotive, Inc. is far larger — about 19.2× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and Maravai LifeSciences Holdings Inc. Class A Common Stock is trading nearer its 52-week high, Rivian Automotive, Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days and Rivian Automotive, Inc. for 61 Days on average.
| MRVI | RIVN | |
|---|---|---|
Market Cap | $977.37M | $18.75B |
Volume | 2,742,564 | 23,581,407 |
Sector | Health | Consumer Cyclical |
52-Week High | $9.00 | $22.45 |
52-Week Low | $2.83 | $12.50 |
Typical Hold Time | 0 Days | 61 Days |
Enterprise Value | $1.08B | $18.79B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Rivian (RIVN) trades at $13.37, down 1.26% as investors react to mixed Q3 2026 delivery results. The stock shows bearish technical signals with oversold RSI readings, while fundamentals reveal improving revenue trends ($5.39B in 2025) but persistent losses (-$3.65B net income). Recent news highlights record vehicle deliveries of 19,248 units in Q3 2026 but disappointment over unchanged full-year guidance.
The outlook remains challenging with significant cash burn and negative margins, though analyst consensus suggests 26% upside to the $16.89 price target. Key risks include execution on R2 production ramp, competitive EV market pressures, and path to profitability. The stock trades near analyst low targets, reflecting cautious optimism about Rivian's scaling potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →About Rivian Automotive, Inc.
Rivian Automotive, Inc. is an automotive technology company. The Company designs and manufactures vans, trucks, and sports utility vehicles, as well as offers repair and maintenance services. Rivian Automotive serves customers in North America and the United Kingdom.
Read more on RIVN →
